HOME > BUSINESS
BUSINESS
- JCR Revises Half-, Full-Year Business Forecasts for FY Ending March 2012
September 14, 2011
- DSP to End Sales of Melbin
September 14, 2011
- Medipal HD, JCR Announce Codevelopment Agreement for 3 Products
September 14, 2011
- FDA Advisory Committee Recommends Approval of Rivaroxaban for SPAF
September 13, 2011
- AZ, Daiichi Sankyo to Launch Nexium on Sept. 15
September 13, 2011
- Takeda Initiates PIII Trials of Antidiabetic TAK-875 in Japan
September 13, 2011
- NBI Initiates PIII Study for BIBF1122 in Japan
September 12, 2011
- TransGenic Submits Patent Application for Novel Lung Cancer Marker Antibody
September 12, 2011
- Santen to Enhance Sales Functions by Creating New Group
September 12, 2011
- Toho Pharmaceutical to Acquire Shouei in January 2012
September 12, 2011
- Astellas to Transfer Distribution Rights for Targocid, Maalox to sanofi-aventis
September 12, 2011
- Astellas Licenses Fully-Human Antibody against Infectious Diseases from Evec
September 12, 2011
- Drug-only Warehouses at Haneda Airportto Start Full-scale Operations this Fall
September 12, 2011
- Former Employee of Regional Wholesaler Sanki Charged with Illegal Drug Sales
September 12, 2011
- More ADCs and Other Anticancer Drugs from Domestic Drug Makers Enter Late Stage Development
September 12, 2011
- Daiichi Sankyo to Transfer Part of R&D Function to Subsidiary
September 12, 2011
- Takeda Begins Domestic PII Clinical Trials for Leuplin Successor TAK-385
September 12, 2011
- Medinet Granted Patent on Cancer Antigen Peptide in 11 European Countries
September 12, 2011
- Helsinn Initiates Global PIII Program for Anamorelin
September 12, 2011
- Takara Bio to Supply Plasmid Vectors for iPS Cell Production to Kyoto University
September 12, 2011
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…